RT @JulianSegan: Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA,
Tweet Content
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action?
@RheumNow ABST0297 #ACR22
https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
Links
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients…
https://tinyurl.com/stvcdtff
Show on Archive Page
On
Display in Search Results
On
PDQ
Off